Newsfeeds - Spark Newswire

4 minute read

Mirati Plays Catch-Up With Amgen, Gilead’s 2nd Try With AIDS Drug, Cytokinetics’ Adcom Test And More: Key Nov FDA Decisions For Biotech Investors

Today, 4:12 AM

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.

AMGN

31 minute read

Earnings

Earnings Scheduled For November 3, 2022

By Benzinga Insights

Today, 4:12 AM

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.

AAOI

1 minute read

UBS Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target of $80

By Benzinga Newsdesk

Today, 4:12 AM

UBS analyst Ashwani Verma initiates coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and announces Price Target of $80.

CYTK

1 minute read

JMP Securities Maintains Market Outperform on Cytokinetics, Raises Price Target to $82

By Benzinga Newsdesk

Today, 4:12 AM

JMP Securities analyst Jason Butler maintains Cytokinetics (NASDAQ:CYTK) with a Market Outperform and raises the price target from $53 to $82.

CYTK

3 minute read

Events
News

Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting

By Charles Gross

Today, 4:12 AM

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data on symptom improvement and quality of life related to treatment with aficamten in REDWOOD-HCM OLE (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM Open Label Extension) in a Late Breaking Clinical Trials session at the Heart Fa

CYTK